Experience with the use of potassium and magnesium aspartate in the treatment of cardiovascular diseases
DOI: 10.32364/2587-6821-2022-6-8-433-442
A.A. Yalymov1, Yu.E. Efremova2, G.G. Shekhyan1, T.G. Charaeva1
1M.F. Vladimirskiy Moscow Regional Research and Clinical Institute, Moscow, Russian Federation
2Acad. E.I. Chazov National Medical Research Center of Cardiology, Moscow, Russian Federation
The article discusses the efficacy and safety profile of potassium and magnesium aspartate agents in the treatment of patients with cardiovascular diseases (CVD). The data demonstrate that potassium and manganese deficiency play an important role in the etiology of CVD and the increased mortality. Hypokalemia and hypomagnesemia are frequently reported in patients with cardiological disorders. The article elucidates the results of multi-center randomized trials in patients with CVD (arterial hypertension, ischemic heart diseases, and cardiac arrhythmia). Also, the article presents two clinical cases with the successful use of potassium and magnesium aspartate (Panangin®, Gedeon Richter) in the treatment of cardiovascular complications associated with electrolyte imbalance. Based on the results of multiple studies involving CVD patients it is suggested that the addition of potassium and magnesium aspartate to the essential therapy improves the effectiveness of CVD management. Thus, potassium and magnesium aspartate can be recommended to cardiac patients.
Keywords: potassium and magnesium aspartate, Panangin, hypomagnesemia, hypopotassemia, arterial hypertension, ischemic heart disease, myocardial infarction, prolonged QT interval, cardiac arrhythmias, ventricular tachycardia.
For citation: Yalymov A.A., Efremova Yu.E., Shekhyan G.G., Charaeva T.G. Experience with the use of potassium and magnesium aspartate in the treatment of cardiovascular diseases. Russian Medical Inquiry. 2022;6(8):433–442 (in Russ.). DOI: 10.32364/2587-6821-2022-6-8-433-442.
About the authors:
Anatoliy A. Yalymov — C. Sc. (Med.), Professor of the Department of Therapy, Faculty of Continuing Medical Education, senior researcher of the Department of Cardiology, M.F. Vladimirskiy Moscow Regional Research and Clinical Institute; 61/2, Shchepkin str., Moscow, 129110, Russian Federation; ORCID iD 0000-0002-5322-3369.
Yuliya E. Efremova — C. Sc. (Med.), senior researcher of the Scientific and Organizational Department, Acad. E.I. Chazov National Medical Research Center of Cardiology; 15a, 3rd Cherepanovskaya str., Moscow, 121552, Russian Federation; ORCID iD 0000-0001-8674-9669.
Grant G. Shekhyan — C. Sc. (Med.), Professor of the Department of Therapy, Faculty of Continuing Medical Education, Head of the Cardiology Department, M.F. Vladimirskiy Moscow Regional Research and Clinical Institute; 61/2, Shchepkin str., Moscow, 129110, Russian Federation; ORCID iD 0000-0003-0442-644X.
Tatyana G. Charaeva — junior researcher of the Cardiology Department, M.F. Vladimirskiy Moscow Regional Research and Clinical Institute; 61/2, Shchepkin str., Moscow, 129110, Russian Federation; ORCID iD 0000-0002-0113-7741. Contact information: Anatoliy A. Yalymov, e-mail: ayalymov@gmail.com
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 09.07.2022.
Revised 02.08.2022.
Accepted 25.08.2022.
2. Stepura O.B., Ostroumova O.D. The use of oral magnesium preparations for the treatment of cardiovascular diseases. RMJ. 2010;3:109 (in Russ.).
3. McLean R.M., Wang N.X. Potassium. Adv Food Nutr Res. 2021;96:89–121. DOI: 10.1016/bs.afnr.2021.02.013.
4. Wolf F., Cittadini A. Chemistry and biochemistry of magnesium. Mol Aspects Med. 2003;24(1–3):3–9. DOI: 10.1016/s0098-2997(02)00087-0.
5. Krogager M.L., Kragholm K., Thomassen J.Q. et al. Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. Eur Heart J Cardiovasc Pharmacother. 2021;7(6):557–567. DOI: 10.1093/ehjcvp/pvab038.
6. Gromova O.A., Torshin I.Yu., Kalacheva A.G. et al. Meta-analysis of clinical trials of cardiovascular effects of magnesium orotate. Terapevticheskii arkhiv. 2015;6:88–97 (in Russ.). DOI: 10.17116/terarkh201587688-97.
7. Weiss J.N., Qu Z., Shivkumar K. Electrophysiology of Hypokalemia and Hyperkalemia. Circ Arrhythm Electrophysiol. 2017;10(3):e004667. DOI: 10.1161/CIRCEP.116.004667.
8. Näppi S.E., Virtanen V.K., Saha H.H. et al. QTc dispersion increases during hemodialysis with low-calcium dialysate. Kidney Int. 2000;57(5):2117–2122. DOI: 10.1046/j.1523-1755.2000.00062.x.
9. Ruksin V.V. Emergency cardiology. SPb.: Nevskiy Dialekt; 1997 (in Russ.).
10. Diaz R., Goyal A., Mehta S.R. et al. Glucose-Insulin-Potassium Therapy in Patients With ST-Segment Elevation Myocardial Infarction. JAMA. 2007;298(20):2399–2405.
11. Woods K.L., Fletcheer S., Foffe C., Haider Y. Intravenous magnesium sulphate in suspected acute myocardial infarction. Results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet. 1992;339(8809):1553–1558. DOI: 10.1016/0140-6736(92)91828-v.
12. Ryan T.J., Antman E.M., Brooks NH. et al. 1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation. 1999;100(9):1016–1030. DOI: 10.1161/01.cir.100.9.1016.
13. Shechter M., Hod H., Chouraqui P. et al. Magnesium therapy in acute myocardial infarction when patients are not candidates for thrombolytic therapy. Am J Cardiol. 1995;75(5):321–323. DOI: 10.1016/s0002-9149(99)80546-3.
14. Yalymov A.A., Zadionchenko V.S., Shekhyan G.G. et al. The use of potassium and magnesium preparations in the cardiac surgery clinic. Consilium Medicum. Khirurgiya. 2012;2:13–17 (in Russ.).
15. Shlyakhto Ye.V. Myocardial metabolism in patients with IHD. Serdechnaya nedostatochnost’. 2003;4(1):19–21 (in Russ.).
16. Hulting J. In-hospital ventricular fibrillation and its relation to serum potassium. Acta Med Scand Suppl. 1981;647:109–116. DOI: 10.1111/j.0954-6820.1981.tb02646.x.
17. Hagengaard L., Sogaard P., Espersen M. et al. Association between serum potas- sium levels and short-term mortality in patients with atrial fibrillation or flutter co-treated with diuretics and rate- or rhythm-controlling drugs. Eur Heart J Cardiovasc Pharmacother. 2020;6(3):137–144. DOI: 10.1093/ehjcvp/pvz024.
18. Pu J., Zhang C., Quan X. et al. Effects of potassium aspartate and magnesium on ventricular arrhythmia in ischemia-reperfusion rabbit heart. J Huazhong Univ Sci Technolog Med Sci. 2008;28(5):517–519. DOI: 10.1007/s11596-008-0506-x.
19. Knüttgen D., Weidemann D., Doehn M. Restoring sinus rhythm after intraoperatively occurring isorhythmic AV dissociation by the use of K-Mg aspartate or Mg aspartate. Magnes Trace Elem. 1990;9(6):303–308.
20. Ryan M., Lown B., Horn H. Comparison of ventricular ectopic activity during 24-hour monitoring and exercise testing in patients with coronary heart disease. N Engl J Med. 1975;292(5):224–229. DOI: 10.1056/NEJM197501302920502.
21. Clinical guidelines. Fibrillation and atrial flutter. 2020. (Electronic resource.) URL: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_FP_TP-unlocked.pdf?ysclid=l7m7tpha9j689295469 (access date: 06.07.2022) (in Russ.).
22. Cappuccio F.P., MacGregor G.A. Does potassium supplementation lower blood pressure? A meta-analysis of published trials. J Hypertens. 1991;9(5):465–473. DOI: 10.1097/00004872-199105000-00011.
23. Krogager M.L., Torp-Pedersen C., Mortensen R.N. et al. Short-term mortality risk of serum potassium levels in hypertension: a retrospective analysis of nationwide registry data. Eur Heart J. 2017;38:104–112. DOI: 10.1093/eurheartj/ehw129.
24. Clinical guidelines. Arterial hypertension in adults. 2020. (Electronic resource.) URL: https://cr.minzdrav.gov.ru/schema/62_2 (access date: 06.07.2022) (in Russ.).
25. Geleijnse J.M., Witteman J.C.M., den Breeijen J.H. et al. Dietary electrolyte intake and blood pressure in older subjects: the Rotterdam Study. J Hypertens. 1996;14(6):737–741. DOI: 10.1097/00004872-199606000-00009.
26. Wirell M.P., Wester P.O., Stegmayr B.G. Nutritional dose of magnesium in hypertensive patients on beta blockers lowers systolic blood pressure: a double-blind, cross-over study. J Intern Med. 1994;236(2):189–195. DOI: 10.1111/j.1365-2796.1994.tb01282.x.
27. Goyal A., Spertus J.A., Gosch K. et al. Serum potassium levels and mortality in acute myocardial infarction. JAMA. 2012;307:157–164. DOI: 10.1001/jama.2011.1967.
28. Shiyovich A., Gilutz H., Plakht Y. Serum potassium levels and long-term post-discharge mortality in acute myocardial infarction. Int J Cardiol. 2014;172(2):e368–e370. DOI: 10.1016/j.ijcard.2013.12.296.
29. Colombo M.G., Kirchberger I., Amann U. et al. Association of serum potassium concentration with mortality and ventricular arrhythmias in patients with acute myocardial infarction: a systematic review and meta-analysis. Eur J Prev Cardiol. 2018;25(6):576–595. DOI: 10.1177/2047487318759694.
30. Xu H., Faxen J., Szummer K. et al. Dyskalemias and adverse events associated with discharge potassium in acute myocardial infarction. Am Heart J. 2018;205:53–62. DOI: 10.1016/j.ahj.2018.06.009.
31. Krogager M.L., Eggers-Kaas L., Aasbjerg K. et al. Short-term mortality risk of serum potassium lev- els in acute heart failure following myocardial infarction. Eur Heart J Cardiovasc Pharmacother. 2015;1(4):245–251. DOI: 10.1093/ehjcvp/pvv026.
32. Trekova N.A., Andrianova M. Yu., Tolstova I.A. et al. Use of a potassium and magnesium asparaginate solution to maintain the balance of potassium and magnesium during cardiosur-gical interventions under extracorporeal circulation. Russian journal of Anaesthesiology and Reanimatology. 2008;5:17–21 (in Russ.).
33. Ravn Jacobsen M., Jabbari R., Glinge C. et al. Potassium disturbances and risk of ventricular fibrillation among patients with ST-segment–elevation myocardial infarction. J Am Heart Assoc. 2020;9(4):e014160. DOI: 10.1161/JAHA.119.014160.
34. Clinical guidelines. Ventricular arrhythmias. Ventricular tachycardia and sudden cardiac death. 2020. (Electronic resource.) URL: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_ZHNR-unlocked.pdf.(access date: 06.07.2022). (in Russ.).
35. Díaz R., Paolasso E.A., Piegas L.S. et al. Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiológicos Latinoamérica) Collaborative Group. Circulation. 1998;98(21):2227–2234. DOI: 10.1161/01.cir.98.21.2227.
36. Liao F., Folsom A.R., Brancati F.L. Is low magnesium concentration a risk factor for coronary heart disease? The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 1998;136(3):480–490. DOI: 10.1016/s0002-8703(98)70224-8.
37. Mehta S.R., Yusuf S., Díaz R. et al. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA. 2005;293(4):437–446. DOI: 10.1001/jama.293.4.437.
38. D’Elia L., Barba G., Cappuccio F.P., Strazzullo P. Potassium intake, stroke, and cardiovascular disease a meta-analysis of prospective studies. J Am Coll Cardiol. 2011;57(10):1210–1219. DOI: 10.1016/j.jacc.2010.09.070.
39. Yang Q., Liu T., Kuklina E.V. et al. Sodium and potassium intake and mortality among US adults: prospective data from the third national health and nutrition examination survey. Arch Intern Med. 2011;171(13):1183–1191. DOI: 10.1001/archinternmed.2011.257.
40. Del Gobbo L.C., Imamura F., Wu J.H. et al. Circulating and dietary magnesium and risk of cardiovascular disease: a systematic review and meta-analysis of prospective studies. Am J Clin Nutr. 2013;98(1):160–173. DOI: 10.3945/ajcn.112.053132.
41. Guasch-Ferré M., Bulló M., Estruch R. et al. Dietary magnesium intake is inversely associated with mortality in adults at high cardiovascular disease risk. J Nutr. 2014;144(12):1956–1962. DOI: 10.3945/jn.113.183012.
42. Yalymov A.A., Shekhyan G.G., Shchikota A.M. et al. Causes and clinical significance. ECG phenomenon of ST segment depression. Consilium Medicum. 2013;15(5):108–118 (in Russ.).
This work is licensed under a Creative Commons «Attribution» 4.0 License.
